203 related articles for article (PubMed ID: 25459660)
1. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.
Munuganti RS; Hassona MD; Leblanc E; Frewin K; Singh K; Ma D; Ban F; Hsing M; Adomat H; Lallous N; Andre C; Jonadass JP; Zoubeidi A; Young RN; Guns ET; Rennie PS; Cherkasov A
Chem Biol; 2014 Nov; 21(11):1476-85. PubMed ID: 25459660
[TBL] [Abstract][Full Text] [Related]
2. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
3. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
4. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
[TBL] [Abstract][Full Text] [Related]
5. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
7. Development of 2-(5,6,7-Trifluoro-1
Leblanc E; Ban F; Cavga AD; Lawn S; Huang CF; Mohan S; Chang MEK; Flory MR; Ghaidi F; Lingadahalli S; Chen G; Yu IPL; Morin H; Lallous N; Gleave ME; Mohammed H; Young RN; Rennie PS; Lack NA; Cherkasov A
J Med Chem; 2021 Oct; 64(20):14968-14982. PubMed ID: 34661404
[TBL] [Abstract][Full Text] [Related]
8. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
9. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.
Wang Y; Dehigaspitiya DC; Levine PM; Profit AA; Haugbro M; Imberg-Kazdan K; Logan SK; Kirshenbaum K; Garabedian MJ
Cancer Res; 2016 Sep; 76(17):5124-32. PubMed ID: 27488525
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).
Ban F; Leblanc E; Li H; Munuganti RS; Frewin K; Rennie PS; Cherkasov A
J Med Chem; 2014 Aug; 57(15):6867-72. PubMed ID: 25025737
[TBL] [Abstract][Full Text] [Related]
11. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
12. The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.
Xu J; Yang X; Deshmukh D; Chen H; Fang S; Qiu Y
Cells; 2020 Apr; 9(5):. PubMed ID: 32354165
[TBL] [Abstract][Full Text] [Related]
13. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
Li H; Mohamed AA; Sharad S; Umeda E; Song Y; Young D; Petrovics G; McLeod DG; Sesterhenn IA; Sreenath T; Dobi A; Srivastava S
Oncotarget; 2015 Jun; 6(17):15137-49. PubMed ID: 25883222
[TBL] [Abstract][Full Text] [Related]
14. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
[TBL] [Abstract][Full Text] [Related]
15. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
17. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
[TBL] [Abstract][Full Text] [Related]
18. Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy.
Shiota M; Ushijima M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Kajioka S; Eto M
Prostate; 2019 Jul; 79(10):1147-1155. PubMed ID: 31077419
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
20. Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.
Munuganti RS; Leblanc E; Axerio-Cilies P; Labriere C; Frewin K; Singh K; Hassona MD; Lack NA; Li H; Ban F; Tomlinson Guns E; Young R; Rennie PS; Cherkasov A
J Med Chem; 2013 Feb; 56(3):1136-48. PubMed ID: 23301637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
